Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Axsome Therapeutics is seeking a Specialty Account Manager (SAM) to execute commercial activities for an assigned geography, establish relationships with customers, and ensure successful promotion of SYMBRAVO, an oral acute migraine medication.